Abstract Background and aims Optimal secondary prevention with medication following stroke or TIA can reduce stroke recurrent recurrence by 80%. In 2023, a post-stroke lipid optimisation audit was conducted in Doncaster Royal Infirmary Hospital. 76% of patients did not achieve the non-HDL target set by NICE (2.6mmol/l), and only 37% had a follow-up lipid profile three months after starting lipid-lowering therapy. To address this gap, a pharmacist-led secondary prevention clinic was piloted to optimise lipid management and other risk factors associated with stroke after discharge. Methods Patients discharged from the stroke unit were screened and triaged on a weekly basis. Inclusion criteria were poorly controlled diabetes, hypertension, hypercholesterolaemia as set out in the standard operating procedure for the pilot. During the clinic, patients had their observations taken and medications reviewed to reduce the risk of further vascular events and given lifestyle counselling including smoking cessation and alcohol intake. Patients requiring lipid lowering injectable therapy were given this during the clinic. After the clinic, patients were discharged to their GP with a clinic letter detailing the appointment outcomes and recommendations Results Of 663 screened patients, 48 were invited and 30 attended the clinics. Mean non-HDL was reduced from 3.19 to 2.59mmol/l. HbA1c improved by 2.9%. Only one patient was readmitted with further vascular events. Conclusions A pharmacist-led medicines optimisation clinic focusing on secondary prevention appears to benefit patients as part of the stroke standard follow up pathway, reducing the risks of further vascular events by addressing the risk factors associated with stroke Conflict of interest Patrick Mok nothing to disclose Ahmad Maatouk nothing to disclose Sarah Chapman nothing to disclose
Mok et al. (Fri,) studied this question.